Last reviewed · How we verify
NCT06620159
Lymphocyte to Procalcitonin Ratio in Covid-19 Patients
trial in COVID-19 in 535 participants. Participants enrolled and being followed up; not accepting new ones.
27 September 2024
Quick facts
| Lead sponsor | Suleyman Demirel University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 535 |
| Start date | 1 April 2020 |
| Primary completion | 27 September 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Suleyman Demirel University
Who can join
Adults 23 to 100, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lymphocyte-to-procalcitonin ratio: a new predictor of prognosis in COVID-19.
Oğuzlar FÇ, Armağan HH, Eryavuz Şengül T, Cesur E. · · 2025 · PMID 41073964 · DOI 10.1186/s12879-025-11726-4
Verify or expand the search:
- PubMed search for NCT06620159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Suleyman Demirel University trials
Trials by the same sponsor.
- NCT07429513 — Promoting Environmental Responsibility Toward Climate Change · NA · not yet recruiting
- NCT07523087 — Effect of a Brief Mindfulness-Based Training on First Clinical Day Stress in First-Year Nursing Students · NA · completed
- NCT07245355 — Contribution of Recreational Exercises to Balance and Muscle Strength in Osteoporosis Risk · NA · not yet recruiting
- NCT07333391 — Individualized Grief Support With Swanson Model · NA · not yet recruiting
- NCT07382830 — Effectiveness of a Visual Feedback Exercise Program Following Lumbar Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06620159 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suleyman Demirel University
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06620159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing